Larson Financial Group’s Apellis Pharmaceuticals APLS Stock Holding History

Larson Financial Group’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-250	Closed	-$10.1K	–	3780
2026 Q1	$10.1K	Sell	250 -216	-46%	-$4.66K	﹤0.01%	2251
2025 Q4	$11.7K	Buy	466 +73	+19%	+$1.71K	﹤0.01%	2025
2025 Q3	$8.89K	Buy	393 +390	+13,000%	+$9.1K	﹤0.01%	2072
2025 Q2	$52	Buy	+3	New	+$56	﹤0.01%	3227
2023 Q4	–	Sell	-11	Closed	-$418	–	1796
2023 Q3	$418	Buy	+11	New	+$483	﹤0.01%	1594

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Larson Financial Group's APLS Position: Q2 2026 in Review

Larson Financial Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 250 shares — an estimated $10.1K sold.

Larson Financial Group first reported a position in APLS in Q3 2023 and held it in 5 quarters. The position peaked at $11.7K in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Larson Financial Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Larson Financial Group sold 250 Apellis Pharmaceuticals shares in Q2 2026, an estimated $10.1K.
Larson Financial Group first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 5 quarters.
Larson Financial Group's Apellis Pharmaceuticals position peaked at $11.7K in Q4 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.